AU471598B2 - 2-amidazolin 2-ylamino substituted quinoxaline and quinazolines as antihypertensive agents - Google Patents

2-amidazolin 2-ylamino substituted quinoxaline and quinazolines as antihypertensive agents

Info

Publication number
AU471598B2
AU471598B2 AU51985/73A AU5198573A AU471598B2 AU 471598 B2 AU471598 B2 AU 471598B2 AU 51985/73 A AU51985/73 A AU 51985/73A AU 5198573 A AU5198573 A AU 5198573A AU 471598 B2 AU471598 B2 AU 471598B2
Authority
AU
Australia
Prior art keywords
amidazolin
quinazolines
ylamino
antihypertensive agents
substituted quinoxaline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU51985/73A
Other languages
English (en)
Other versions
AU5198573A (en
Inventor
MICHAEL SNARE'Sand GEOFFREY NOEL THOMAS JOHN CHRISTOPHER DANTLEWICZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of AU5198573A publication Critical patent/AU5198573A/en
Application granted granted Critical
Publication of AU471598B2 publication Critical patent/AU471598B2/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU51985/73A 1972-02-29 1973-02-08 2-amidazolin 2-ylamino substituted quinoxaline and quinazolines as antihypertensive agents Expired AU471598B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9196/72 1972-02-29
GB919672A GB1381979A (en) 1972-02-29 1972-02-29 Amino derivatives of quinoline quinoxaline and quinazoline
GB5162972 1972-11-08

Publications (2)

Publication Number Publication Date
AU5198573A AU5198573A (en) 1974-08-08
AU471598B2 true AU471598B2 (en) 1976-04-29

Family

ID=26242776

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51985/73A Expired AU471598B2 (en) 1972-02-29 1973-02-08 2-amidazolin 2-ylamino substituted quinoxaline and quinazolines as antihypertensive agents

Country Status (16)

Country Link
US (1) US3890319A (enExample)
JP (2) JPS5754516B2 (enExample)
AR (1) AR213705A1 (enExample)
AU (1) AU471598B2 (enExample)
BE (1) BE795970A (enExample)
CA (1) CA981678A (enExample)
CH (2) CH576975A5 (enExample)
DE (1) DE2309160A1 (enExample)
ES (2) ES411804A1 (enExample)
FI (1) FI63757C (enExample)
FR (1) FR2181776B1 (enExample)
GB (1) GB1381979A (enExample)
IE (1) IE37519B1 (enExample)
MX (1) MX3042E (enExample)
NL (1) NL159102B (enExample)
SE (1) SE417204B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1463520A (en) * 1974-09-06 1977-02-02 Pfizer Ltd Process for the production of imidazolines
JPS5373571A (en) * 1976-12-10 1978-06-30 Otsuka Pharmaceut Co Ltd Carbostyril derivatives
JPS542338A (en) 1977-04-22 1979-01-09 Sandoz Ag Pharmaceutical composition
US4188393A (en) 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
FR2449087A2 (fr) * 1979-02-16 1980-09-12 Rhone Poulenc Ind Nouveaux derives de l'isoquinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent
US4486432A (en) * 1982-09-30 1984-12-04 Eli Lilly And Company Quinoxalinedione leukotriene release inhibitors
FR2541680B1 (fr) * 1983-02-24 1985-06-14 Rhone Poulenc Sante Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent
JPS6118950U (ja) * 1984-07-10 1986-02-03 財団法人鉄道総合技術研究所 トロリ線の給油装置
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5215991A (en) * 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5252595A (en) * 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
AU688380B2 (en) * 1993-10-13 1998-03-12 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
AU699041B2 (en) * 1993-12-17 1998-11-19 Board Of Regents Of The University Of Nebraska, The 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
CZ175496A3 (en) * 1993-12-17 1996-11-13 Procter & Gamble 6-(2-imidazolinylamino)quinoxaline compounds usable as alpha-2 adrenoceptor agonists
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
CN1046501C (zh) * 1994-02-08 1999-11-17 阿尔康实验室公司 新型硫脲复合物及制备硝基芳基亚氨基杂环的方法
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
EP0944622A1 (en) * 1996-11-25 1999-09-29 The Procter & Gamble Company 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
AU5433898A (en) * 1996-11-25 1998-06-22 Procter & Gamble Company, The 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists
US6306877B1 (en) 1999-08-09 2001-10-23 The Procter & Gamble Co. Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
AU730369B2 (en) 1996-11-25 2001-03-08 Board Of Regents Of The University Of Nebraska, The Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
WO1998023610A1 (en) * 1996-11-25 1998-06-04 The Procter & Gamble Company 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists
US6172095B1 (en) 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US6486190B1 (en) 1997-11-24 2002-11-26 The Procter & Gamble Company 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
WO2004073708A1 (en) 1998-12-17 2004-09-02 Dean Thomas R Brinzolamide and brimonidine for treating ocular conditions
CN100569291C (zh) 2000-07-14 2009-12-16 阿勒根公司 含有α-2肾上腺素能激动剂的组合物
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20050026924A1 (en) * 2000-07-14 2005-02-03 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
PT2153819E (pt) * 2000-07-14 2012-11-14 Allergan Inc Utilização de um componente para aumento de solubilidade numa composição aquosa compreendendo tartarato de brimonidina
DE10161767A1 (de) * 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
MXPA05003665A (es) * 2002-10-08 2005-06-08 Allergan Inc Metodo de uso de (2-imidazolin-2-ilamino) quinaxolinas en el tratamiento de la demencia y enfermedad de parkinson.
MXPA05003664A (es) * 2002-10-08 2005-06-08 Allergan Inc Agonistas del adrenoceptor alfa 2b o 2b/2c para tratamiento de neurodegeneracion.
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
ES2593113T3 (es) 2003-08-07 2016-12-05 Allergan, Inc. Composiciones para el suministro de agentes terapéuticos en los ojos y métodos para obtener y usar los mismos
CN103664802B (zh) * 2003-08-14 2015-08-05 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
WO2005039567A1 (en) * 2003-10-08 2005-05-06 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
CN101426502A (zh) 2004-05-25 2009-05-06 桑斯罗萨医药发展公司 治疗或预防炎症性皮肤疾病的化合物、制剂及方法
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
ES2364901T3 (es) 2005-11-15 2011-09-16 Array Biopharma, Inc. Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
WO2008074068A1 (en) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
WO2008144399A1 (en) * 2007-05-18 2008-11-27 Bausch & Lomb Incorporated COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US7842714B2 (en) * 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
CA2777223C (en) 2009-10-06 2017-10-24 Allergan, Inc. 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
DK2552449T3 (en) 2010-03-26 2017-06-19 Galderma Res & Dev COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM
MX2012010823A (es) 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo de telangiectasia.
CN102883709A (zh) 2010-04-07 2013-01-16 阿勒根公司 用于眼用制剂的防腐组合物联合
JP2013523828A (ja) 2010-04-07 2013-06-17 アラーガン インコーポレイテッド 眼科用組成物のための保存剤の組み合わせ
AU2011282683B2 (en) 2010-07-29 2016-12-22 Allergan, Inc. Preservative free brimonidine and timolol solutions
EP2444068B2 (en) 2010-10-21 2017-12-06 Galderma S.A. Brimonidine gel composition
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
CA2843251A1 (en) * 2011-07-25 2013-01-31 Santosh C. Sinha N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors
GR1009419B (el) 2017-11-07 2018-12-14 Φαρματεν Αβεε Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560501A (en) * 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) * 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.

Also Published As

Publication number Publication date
IE37519L (en) 1973-08-29
MX3042E (es) 1980-03-04
AR213705A1 (es) 1979-03-15
BE795970A (fr) 1973-08-27
FI63757C (fi) 1983-08-10
FR2181776B1 (enExample) 1976-08-13
CH577500A5 (enExample) 1976-07-15
GB1381979A (en) 1975-01-29
IE37519B1 (en) 1977-08-17
NL7302799A (enExample) 1973-08-31
JPS5745439B2 (enExample) 1982-09-28
NL159102B (nl) 1979-01-15
AU5198573A (en) 1974-08-08
JPS5625176A (en) 1981-03-10
FR2181776A1 (enExample) 1973-12-07
FI63757B (fi) 1983-04-29
CA981678A (en) 1976-01-13
US3890319A (en) 1975-06-17
ES412102A1 (es) 1976-05-16
CH576975A5 (enExample) 1976-06-30
JPS4897878A (enExample) 1973-12-13
ES411804A1 (es) 1976-05-01
DE2309160A1 (de) 1973-09-27
JPS5754516B2 (enExample) 1982-11-18
SE417204B (sv) 1981-03-02

Similar Documents

Publication Publication Date Title
AU471598B2 (en) 2-amidazolin 2-ylamino substituted quinoxaline and quinazolines as antihypertensive agents
CA1016737A (en) Heterocyclic flavoring compositions and processes
CA956956A (en) Quinazolinone derivatives and preparation thereof
AU467499B2 (en) Imidazo-diazepines, pyrimidines and imidazoles
CA990726A (en) Derivatives of 1,2,3,4-tetrahydroisoquinoline production of the same and composition thereof
CA967574A (en) 3-sulphoalkyl-6-hydroxy-pyrid-(2)-ones, their manufacture and use
CA977350A (en) Halogeno-6-hydroxy-pyridone-(2) compounds, their manufacture and use
IL41728A0 (en) Quinoxaline derivatives and pesticidal compositions
CA1005059A (en) Quinazoline compounds
CA1001165A (en) Formamidine derivatives and the composition containing same
CA993874A (en) Pyrimidines and process of making the same
CA962679A (en) Quinazolinone derivatives
AU472291B2 (en) Chroman-5-ols and their use as anti-hypertensive agents
CA1012164A (en) N-aroyl-n'-(alkylhydroxyphenyl)alkanoylhydrazines
CA956958A (en) 3,4-dihydro-2(1h)-quinazolinones and preparation thereof
CA983930A (en) 6,7-methylenedioxy-2(1h)-quinazolinone derivatives
CA859169A (en) 1-phenoxymethyl-3,4-dihydro and 1,2,3,4-tetrahydroisoquinoline derivatives
CA912561A (en) Quinazoline derivatives
CA847364A (en) Heterocyclic n,n'-diglycidyl compounds
CA831985A (en) 2-methoxy-4-(n4-glutarylsulfanilamido) quinazoline
CA809662A (en) 5-substituted aza-dibenzocycloheptenes and the preparation thereof
CA803832A (en) Zone and line finding
AU434653B2 (en) 3,4-dihydro-2(1h)-quinazolinones and preparation thereof
CA845725A (en) Heterocyclic compounds, their preparation and use
AU479013B2 (en) Benzoyloxybenzoates and compositions stabilized therewith